DESTINY-Breast03 Phase 3 Study Results
Prior Therapies
DESTINY-Breast04
Hormone receptor-positive
T-DXD
(n = 331)
TPC
(n = 163)
All patients
T-DXD
(n=373)
TPC
(n = 184)
Lines of systemic therapy (metastatic setting)
Number of lines, median (range)
3 (1-9)
3 (1-8)
3 (1-9)
3 (1-8)
Number of lines, n (%)
23 (7)
14 (9)
39 (10)
19 (10)
1
2
85 (26)
41 (25)
100 (27)
53 (29)
23
223 (67)
108 (66)
234 (63)
112 (61)
Lines of chemotherapy (metastatic setting)
Number of lines, median (range)
1 (0-3)
1 (0-2)
1 (0-3)
1 (0-2)
Number of lines, n (%)
0
1
1 (0.3)
1 (0.6)
1 (0.3)
203 (61.3)
93 (57.1)
221 (59.2)
2
124 (37.5)
69 (42.3)
145 (38.9)
≥3
3 (0.9)
0
6 (1.6)
1 (0.5)
100 (54.3)
83 (45.1)
0
Lines of endocrine therapy (metastatic setting)
Number of lines, median (range)
2 (0-7)
2 (0-6)
2 (0-7)
2 (0-6)
Number of lines, n (%)
28 (8)
17 (10)
60 (16)
34 (18)
0
105 (32)
49 (30)
108 (29)
51 (28)
1
2
≥3
110 (33)
53 (33)
115 (31)
54 (29)
88 (27)
44 (27)
90 (24)
45 (24)
Prior targeted cancer therapy, n (%)
Targeted therapy
259 (78)
132 (81)
279 (75)
140 (76)
CDK4/6 inhibitor
233 (70)
115 (71)
239 (64)
119 (65)
Based on derived data, which includes protocol deviations. CDK, cyclin-dependent kinase; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
Daiichi-Sankyo
11View entire presentation